pendent Ag such as the capsular polysaccharides of HIB,3 Streptococcus pneumoniae, and Neisseria meningitidis (1-4) These encapsulated bacteria are responsible for most of the serious infections of childhood and until recently HIB was the leading cause of meningitis in young children (1) . Although passively administered antibody directed to the capsular polysaccharide of HIB clearly protects children, attempts to immunize infants with pure polysaccharide vaccines have failed (1, 5).
More immunogenic vaccines have been produced by linking polysaccharides to protein carrier molecules (i.e., polysaccharide-conjugates) which results in the generation of Th cells that recognize carrier epitopes. In 1990 two conjugated vaccines for HIB were licensed for use in infants at 2 mo of age. One conjugate vaccine, PRP-OMPC, is produced by covalently linking the polysaccharide of HIB to an OMPC derived from group B N. meningitidis. The other vaccine, PRP-CRM197, links oligosaccharide to a variant of diphtheria toxin (CRM197). Both preparations have been shown to be highly efficacious in preventing invasive HIB disease (6, 7). However, the PRP-OMPC vaccine produces measurable responses in infants at 2 mo of age after one immunization whereas PRP-CRM197 does not (6, 8). The cellular mechanism for this early primary response to PRP-OMPC is not defined.
We report that PRP-OMPC results in T cell-independent splenomegaly with a n increase number of macrophages. We speculate on the relevance of this PRP-OMPC effect to early primary responses and the significance for future vaccine development. Cell prollferations. Splenocytes at 1 x lo5 cells/0.2 ml in DME 10% FCS with penicillin (100 U/ml) and streptomycin (100 pg/ml) were incubated in 96-well microtiter round bottom wells (Costar) with 4 pg/ml Con A or medium for 7 2 h a t 37°C in 10% COz incubator.
MATERIALS AND METHODS

Animals and immunization.
During the last 12 h each sample was pulsed with 1 pCi of [3H]TdR and then harvested onto glass fiber strips by using a cell harvester.
The amount of incorporated [3H]TdR was assessed by liquid scintillation counting and the results are expressed as the mean proliferation in cpm of quadruplicate samples.
Mouse Ig ELISA. Serum IgG was measured by ELISA using goat anti-mouse IgG capture antibody (Tago, Burlingame, CA) and goat anti-mouse IgG alkaline phosphatase conjugate (Tago). The assays were sensitive to approximately 1 ng/ml of mouse Ig.
RESULTS
Spleen size after immunization.
We determined the spleen size of BALB/c mice 7 days after immunization with PRP-OMPC vaccine, PRP-CRM197 vaccine, or saline. The length and width of spleens were measured after surgical removal and the surface areas (length cm X width cm) were compared (Fig. 1A) . The geometric mean surface area of 12 spleens of mice immunized with PRP-OMPC was significantly greater than that of the 11 saline controls ( p < 0.01). The spleens of nine mice immunized with PRP-CRM197 vaccine were not larger than those of controls. To determine if the effect was due to the aluminum hydroxide diluent of PRP-OMPC vaccine, mice received injections with aluminum hydroxide diluent alone and no significant increase spleen size was demonstrated (Fig. 1A) . In addition, mice received injections with PRP-CRM197 mixed with aluminum hydroxide diluent and no size increase was noted. Two mice were after immunization with PRP-OMPC vac- immunized with 50 pg of LPS and the surface area was the same as saline controls. Finally, mice received injections with PRP-OMPC vaccine diluted in saline and a significant increase of spleen size was again noted as compared to saline controls ( p < 0.05) although the size increase was less than that observed with PRP-OMPC administered in aluminum hydroxide.
Splenocyte number after immunization. We also examined the number of splenocytes obtained from individual spleens. Mice immunized with PRP-OMPC demonstrated significantly increased numbers of splenocytes as compared to saline controls (Fig. 1B) ( p = 0.0001). A significant increase in number of splenocytes was also noted for mice receiving PRP-OMPC in saline although the number of splenocytes were less than those immunized with PRP-OMPC in aluminium hydroxide diluent.
Again no significant increases were noted for mice receiving PRP-CRM 197 vaccine, LPS, or aluminum hydroxide diluent alone.
Analytic flow cytometry and immunohistochemical staining. By flow cytometry we examined the splenocytes after immunization to determine the cell type(s) that were increased. The cell size distribution were compared for mice of each group by determining 90" angle light scatter vs forward angle light scatter by flow cytometry. The 90' scatter is indicative of granularity and forward scatter is increased by size. Thus large cells with increased granularity are located in the upper right hand quadrant. Mice immunized with PRP-OMPC demonstrated an increased number of large cells as compared to saline or PRP-CRM197 immunized controls (Fig. 2) . The splenocytes were stained for surface markers of B cells (B220), T cells (Thy-1), dendritic cells (33D1), and macrophages (Mac-1). Consistently, mice immunized with PRP-OMPC had an increased percentage of cells expressing Mac-1 Ag as compared to saline or PRP-CRM197 immunized controls (Fig. 3) . PRP-OMPC immunized mice also demonstrated a consistent decrease in the percentage of cells expressing B220 and Thy-1 (Fig. 3) . No increase in 33D1 expression was noted suggesting the cells were not dendritic cells (data not shown) (9) . Mice immunized with aluminum hydroxide diluent, PRP-CRM197 vaccine in saline, or PRP-CRM197 vaccine in aluminum hydroxide, did not demonstrate increases in Mac-1 expression as compared to controls (data not shown).
To confirm the flow cytometry results we examined the spleens histologically and by an immunohistochemical method stained frozen sections for B cell (B220). T cell (Thy-1), and macrophage-specific (Mac-1 and p150, 95) cell surface protein expression. Mice immunized with PRP-OMPC had a marked decrease in the number of splenic follicles with a n increase in the red pulp area as compared to controls (Fig. 4, a and e ) . An in the number of B cells and an increase in Mac-l+ cells in the red pulp area were noted (Fig. 4, c and 9) . A decrease in the number of Thy-l+ cells was also noted (data not shown). The splenocytes were stained with 8C5 mAb that recognizes ~1 5 0 . 9 5 Ag (CD1 IC) found on macrophages and granulocytes. The PRP-OMPC-immunized mice demonstrated an increase in CD1 IC+ cells as compared to the saline injected control (Fig. 4 , d and h) . In addition to macrophages, an increase number of granulocytes and megakaryocytes were noted in the PRP-OMPC-immunized mice (Fig. 4e) .
Functional assays. Inasmuch as the relative number of B cells and T cells were decreased after immunization with PRP-OMPC, we examined the functional activity of the remaining T cells. To control for differences in number of T cells, we first nylon wool-depleted splenocytes obtained from mice immunized with either PRP-OMPC, PRP-CRM197, or saline. Proliferation assays were then performed on the T cell-enriched populations and no functional impairment of the T cells from PRP-OMPCimmunized mice was observed (Fig. 5) . NK activity was examined using splenocytes for mice immunized with PRP-OMPC, PRP-CRM197, or saline. N o purification for NK cells was used and thus the assay for NK cell activity (Fig. 6) . Furthermore, when the splenocytes were examined by flow cytometry, a n increase in Mac-1 and MHC class I1 expression occurred after immunization with PRP-OMPC vaccine (Fig. 7) . A s expected, no cells expressing B220 (B cells) were noted although a small percentage of Thy-l+ cells were observed. Others have also noted Thy-l+ cells in SCID mice (10). After PRP-OMPC immunization, the Thy-l+ cells could no longer be detected (data not shown). To document that the mice with increased spleen size had no lymphocyte function, mouse serum Ig was measured by ELISA. The three SCID mice with increased spleen size all had less than 0.010 Fg/rnl of serum IgG with a control BALB/c mouse serum measuring 125 pg/ml.
DISCUSSION
In this study, mice immunized with PRP-OMPC vaccine developed marked increases in spleen size and splenocyte number that were not observed after immunization with another HIB-conjugate vaccine, PRP-CRM 197. By analytic flow cytometry and immunohistochemical methods we demonstrated that the increased cell population consisted of large cells expressing Mac-1 and pl50.95 Ag and the cell morphology was characteristic of splenic macrophages. An increase in the number of granulocytes and megakaryocytes was also noted but not quantitated. The PRP-OMPC effect on macrophages was enhanced by administration of PRP-OMPC vaccine with the supplied aluminum hydroxide diluent. Finally. SCID mice developed splenomegaly with an increase in Mac-1 and MHC class I1 expression after PRP-OMPC immunization. Thus the macrophage effect occurred via a T cell-independent pathway.
Macrophages express the CD11 -CD18 family of integrins including LFA-1, Mac-1 (CR3). a n d ~1 5 0 . IFN-7, IL-1, IL-3, CSF-1, ent pathways [ 13) . The T cell-independent pathway has TNF-a. and GM-CSF (1 3-17) . These cytokines are pro-been recently defined in the SCID mouse model of chronic duced by fibroblasts and endothelial cells (GM-CSF, infection with Listeria rnonocytogenes [ 13). Mice homo- Even though SCID mice lack functional T and B cells, they do have normal NK and macrophage cell number and function (23) . In SCID mice T cell-independent activation of macrophages by Listeria organisms requires both IFN-7 (produced by NK cells) and IL-1 (1 3, 14) . Those studies suggest that after an infection, macrophages are stimulated to release TNF and other product(s). NK cells are then activated to produce IFN-7 which results in increased MHC class I1 expression by the SCID macrophages (24) .
In our study, PRP-OMPC immunization of SCID mice resulted in a n increase number of splenic macrophages. Although we cannot exclude the possibility that macrophages were recruited to the spleen, we propose that macrophage proliferation occurred. Inasmuch as NK cells can mediate macrophage activation, we suggest that T cell-independent proliferation can occur as well. TNF-a and CSF-1 (produced by macrophages) and GM-CSF (produced by macrophages and NK cells) have all been shown to induce macrophage proliferation in vitro (1 5-18) . In addition, the increased number of granulocytes and me-
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gakarocytes could result from NK-derived cytokines, as IL-3 and GM-CSF stimulate progenitors of these cell types (20, 25, 26) .
The components of PRP-OMPC vaccine that elicit macrophage proliferation are not defined in this study. Recently, the major membrane protein of OMPC has been identified a s the class 2 porin protein (27) . This protein has been termed MIEP and contains Th cell carrier epitopes. MIEP was also found to be mitogenic for both human and mouse lymphocytes (27) . When purified MIEP was conjugated to polysaccharide, the PRP-MIEP conjugate vaccines demonstrated immunogenicity similar to PRP-OMPC preparations. However, MIEP did not retain the adjuvancy characteristics of OMPC. When OMPC was administered with a nonlinked soluble protein (e.g., tetanus toxoid), an increase response to the protein occurred. In contrast, mixture with MIEP did not result in an increase response to the protein. Thus, components of OMPC other then MIEP may be important in generating protective responses to PRP-OMPC.
MIEP could be the component of the vaccine that induced increases in the number of macrophages. However, the decrease in T cell and B cell percentages noted in the spleens, is not suggestive of a lymphocyte mitogenic response. Furthermore, because the effect on macrophages occurred in a T cell-independent fashion, a MIEP-induced lymphocyte secondary effect can be excluded. OMPC also contains small amounts of LPS and liposomal structures of other lipids (28) . Macrophages are known to bind LPS and other lipids through Mac-1 and Mo-2(CD 14) molecules (28.29) . We doubt that LPS in PRP-OMPC is inducing macrophage proliferation because LPS derived from Escherichia coli at a dose of 50 fig had no effect on splenic macrophage number or spleen size in our study. However, we did not study meningococcal LPS and thus cannot completely exclude an LPS effect. Alternatively, cytokine release from macrophages may occur after exposure to so called "super Ag" such as staphylococcal exotoxin B and toxic shock syndrome toxin (30) . These Ag cause T cell proliferation through direct binding to TCR (31) . If PRP-OMPC acted by a similar mechanism, one might expect an increase in T cell numbers that was not observed in our study. Thus the mechanism for T The T cell-independent effect of PRP-OMPC on murine splenic macrophages may have relevance to the immune response to polysaccharide conjugate vaccines in children. PRP-OMPC produces a response characterized by IgGl and IgM antipolysaccharide antibody after a single immunization at 2 mo of age although PRP-CRM197 vaccine does not (6) (7) (8) . We propose that the OMPC of the PRP-OMPC vaccine causes T cell-independent macrophage activation and proliferation. The activated macrophages would then release cytokines that enhance the immune response of B cells. In fact, we have previously demonstrated that human polysaccharide-specific B cells respond to IL-6 (a cytokine produced by macrophages a s well as T cells) (32) . We propose that PRP-OMPC causes a n early primary response through this mechanism. We also suggest that macrophage proliferation may be the cellular mechanism responsible for the previously described "adjuvant effect."
MHC
PRP-OMPC administered in aluminum hydroxide results in enhanced macrophage proliferation over that seen with PRP-OMPC alone. This enhancement could be due to the presumed depot effect of aluminum hydroxide, a known adjuvant (33).
Further understanding of the unique properties of PRP-OMPC may prove important as OMPC is currently being evaluated as a carrier for other polysaccharide conjugate vaccines. To conjugate T cell-independent Ag with molecules that activate T cells or macrophages nonspecifically may well enhance immunogenicity. Of course, the potential hazards of this approach will also need to be carefully examined.
